公开(公告)号：WO2020198450A1

公开(公告)日：2020-10-01

申请号：PCT/US2020/024919

申请日：2020-03-26

Applicant: THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  THE GENERAL HOSPITAL CORPORATION

Inventor： LI, Bo ,  HACOHEN, Nir

IPC: A61K38/02 ,  A61K39/395 ,  A61P31/16

Abstract: Methods of treating influenza A are provided, comprising administering to a subject at least one agent selected from a WDR7 inhibitor, a CCDC115 inhibitor, a TMEM199 inhibitor, and a CMTR1 inhibitor

公开(公告)号：WO2020127754A1

公开(公告)日：2020-06-25

申请号：PCT/EP2019/086334

申请日：2019-12-19

Applicant: PARIS SCIENCES ET LETTRES - QUARTIER LATIN ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  HIFIBIO (HK) LIMITED ,  ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： GRIFFITHS, Andrew ,  AMIGORENA, Sebastien ,  LANTZ, Olivier ,  WEITZ, David ,  NGHE, Philippe ,  GERARD, Annabelle

IPC: C12Q1/6806 ,  C12N15/10

Abstract: The invention concerns a method for identifying cognate pairs of a ligand species and a receptor species, comprising co-compartmentalising ligand species and receptor species to form a set of microreactors, each microreactor comprising at least one ligand species and preferably at least one receptor species; assaying the recognition between ligands and receptors in each microreactor and based on this assay, classifying each microreactor as positive when at least one ligand species and at least one receptor species in the microreactor recognize one with the other or negative when no ligand species and no receptor species recognize in the microreactor; identifying ligand species and receptor species contained in each positive microreactor; establishing a subset of positive microreactors containing the same receptor species; determining the probability that in a given subset of positive microreactors containing the same receptor species, the ligand species recognizing the receptor species corresponds to the most frequent co-compartmentalized ligand species; and if the determined probability is greater than a predetermined threshold, identifying as a cognate pair the receptor species and the most frequent co-compartmentalized ligand species.

公开(公告)号：WO2014145599A2

公开(公告)日：2014-09-18

申请号：PCT/US2014/030394

申请日：2014-03-17

Applicant: THE BROAD INSTITUTE, INC. ,  THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  MASSACHUSETTS INSTITUTE OF TECHNOLOGY ,  ZHANG, Feng ,  BRIGHAM, Mark, D. ,  CONG, Le ,  KONERMANN, Silvana

Inventor： ZHANG, Feng ,  BRIGHAM, Mark, D. ,  CONG, Le ,  KONERMANN, Silvana

IPC: C12N15/864

CPC classification number: C12N7/00 ,  C12N15/86 ,  C12N2750/14043 ,  C12N2750/14121 ,  C12N2750/14151 ,  C12N2750/14152 ,  C12P19/34 ,  C12Q1/686 ,  C12Q1/701 ,  C12Q2600/158

Abstract: The present invention generally relates to methods and compositions used delivery of gene editing compositions including transcriptional effectors with parvovirus and preferred methods for making same.

Abstract translation: 本发明一般涉及使用包含转录效应子与细小病毒的基因编辑组合物的递送的方法和组合物以及制备该细胞病毒的优选方法。

公开(公告)号：WO2012061488A1

公开(公告)日：2012-05-10

申请号：PCT/US2011/058942

申请日：2011-11-02

Applicant: TOPCODER, INC. ,  THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  LONDON BUSINESS SCHOOL ,  LAKHANI, Karim ,  BOUDREAU, Kevin ,  LYDON, Michael

Inventor： LAKHANI, Karim ,  BOUDREAU, Kevin ,  LYDON, Michael

IPC: G06Q10/00

CPC classification number: G06Q10/101

Abstract: An open innovation event is conducted with more than one (or more) rule regimes. A rule choice module is used to facilitate selection by participants of a desired rule regime from a choice of possible rule regimes. An assignment module assigns participants to groups based at least in part on their rule regime selection. A problem distribution module electronically distributes to participants a problem to be solved during the open innovation event. An event operations module conducts the event with one rule regime applying to one group, so that each of two participant groups are subject to different rule regimes, with the different rule regimes selected from the choice of possible rule regimes. An evaluation module is used to evaluate winning solutions. A prize distribution module is used to manage distribution of prizes based on the rule regime applicable to the group in which a winning submitter was assigned.

Abstract translation: 一个开放的创新活动是与多个（或多个）规则制度进行的。 规则选择模块被用于便于参与者从选择可能的规则制度中选择所需规则制度。 任务模块至少部分地基于他们的规则制度选择将参与者分配给组。 问题分配模块向参与者电子分发在开放创新事件期间要解决的问题。 事件操作模块以一个规则制度对一个组进行事件，使得两个参与者组中的每一个受到不同的规则制度的约束，其中不同的规则制度选自可能的规则制度。 评估模块用于评估获胜解决方案。 奖励分配模块用于根据适用于分配获胜者的组的规则制度来管理奖品的分配。

公开(公告)号：WO2007130429A3

公开(公告)日：2007-11-15

申请号：PCT/US2007/010587

申请日：2007-05-02

Applicant: THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  MAZITSCHEK, Ralph ,  KWIATKOWSKI, Nicholas, Paul ,  BRADNER, James, Elliott

Inventor： MAZITSCHEK, Ralph ,  KWIATKOWSKI, Nicholas, Paul ,  BRADNER, James, Elliott

IPC: A61K31/33 ,  A61K31/47 ,  A61K31/44 ,  A61K31/415 ,  A61K31/335 ,  C07D215/00 ,  C07D233/00 ,  C07D263/00 ,  C07D277/68 ,  C07D403/00 ,  C07D405/00 ,  C07D413/00

Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel inhibitors of histone deacetylases, tubulin deacetylases, and/or aggresome inhibitors, and pharmaceutically acceptable salts and derivatives thereof. The inventive compounds fall into two classes — "isorubacin" class and "isoisotubacin" class- — all of which include a 1,3-dioxane core. The present invention further provides methods for treating disorders regulated by histone deacetylase activity, tubulin deacetylase activity, and/or the aggresome (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, protein degradation disorders, protein deposition disorders, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.

公开(公告)号：WO2007117639A2

公开(公告)日：2007-10-18

申请号：PCT/US2007/008647

申请日：2007-04-06

Applicant: THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  MYERS, Andrew, G. ,  BRUBAKER, Jason, D. ,  SUN, Cuixiang ,  WANG, Qiu

Inventor： MYERS, Andrew, G. ,  BRUBAKER, Jason, D. ,  SUN, Cuixiang ,  WANG, Qiu

IPC: A61K31/65

CPC classification number: C07C237/26 ,  C07C323/61 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2603/46 ,  C07C2603/52 ,  C07D205/04 ,  C07D213/56 ,  C07D277/30 ,  C07D277/66 ,  C07D295/155

Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti- microbial agents or anti-pro liferative agents in the treatment of diseases of humans or other animals.

Abstract translation: 四环素类抗生素在过去50年的传染病治疗中发挥了重要作用。 然而，四环素在人类和兽医药物中的使用量的增加已经导致了以前易受四环素抗生素影响的许多生物体之间的抵抗。 所述四环素和四环素类似物的模块合成为通过先前的四环素合成和半合成方法先前无法接近的各种四环素类似物和聚环状体提供了有效和对映选择性的途径。 这些类似物可以用作抗微生物剂或抗增生剂来治疗人类或其他动物的疾病。

公开(公告)号：WO2007082048A2

公开(公告)日：2007-07-19

申请号：PCT/US2007/000788

申请日：2007-01-11

Applicant: THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  MARCUS, Charles, M.

Inventor： MARCUS, Charles, M.

IPC: A61K49/10

CPC classification number: A61K49/18 ,  A61B5/055 ,  G01R33/282 ,  G01R33/5601

Abstract: The present invention generally relates to methods for accelerating the ex vivo induction of nuclear hyperpolarization in imaging agents.

Abstract translation: 本发明一般涉及用于加速显像剂中离体诱导核超极化的方法。

公开(公告)号：WO2007044035A2

公开(公告)日：2007-04-19

申请号：PCT/US2005/044349

申请日：2005-12-08

Applicant: The President And Fellows Of Harvard College

Inventor： KING, Gavin, M.

IPC: B81C99/00

CPC classification number: C23C14/06 ,  B82Y10/00 ,  C23C14/5873 ,  H01J37/3005 ,  H01J2237/31732 ,  H01J2237/3174 ,  H01L21/02238 ,  H01L21/0332 ,  H01L21/0337 ,  H01L21/30604 ,  H01L21/3065 ,  H01L21/31662 ,  H01L21/3185 ,  Y10S977/856 ,  Y10S977/857 ,  Y10S977/888 ,  Y10S977/89 ,  Y10S977/891

Abstract: The invention provides a method for forming a patterned material layer on a structure, by condensing a vapor to a solid condensate layer on a surface of the structure and then localized removal of selected regions of the condensate layer by directing a beam energy at the selected regions. The structure can be processed, with at least a protion of the patterned solid condensate layer on the structure surface, and then the solid condensate layer removed.Further there can be stimulated localized reaction between the solid condensate layer and the structure by directing a beam of energy at at least one selected region of the condensate layer.

Abstract translation: 本发明提供了一种用于在结构上形成图案化材料层的方法，通过将蒸气冷凝到结构表面上的固体冷凝物层，然后通过将冷凝物层的选定区域局部去除 在选定的区域引导光束能量。 可以对结构进行处理，在结构表面上至少具有图案化的固体冷凝物层的一部分，然后去除固体冷凝物层。此外，可以通过将固体凝聚物层的一束 能量在冷凝层的至少一个选定区域。

公开(公告)号：WO2007008226A2

公开(公告)日：2007-01-18

申请号：PCT/US2005/029294

申请日：2005-08-17

Applicant: THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  LIU, David, R. ,  KANAN, Matthew, William ,  ROZENMAN, Mary, M.

Inventor： LIU, David, R. ,  KANAN, Matthew, William ,  ROZENMAN, Mary, M.

IPC: C07C37/11

CPC classification number: C07C45/28 ,  C07B37/04 ,  C07B37/10 ,  C07C45/34 ,  C07C231/12 ,  C07D273/00 ,  C07C233/20 ,  C07C235/78

Abstract: A novel palladium-mediated carbon-carbon bond forming reaction has been discovered using DNA-templated chemistry. The inventive reaction involves the palladium-mediated coupling of a terminal alkyne with an alkene to form an enone. A catalytic amount of palladium may be used in the reaction if an oxidant is present. The reactions is also compatible with a variety of organic solvent as well as aqueous solution. Both intermolecular and intramolecular reactions have been demonstrated. This novel carbon-carbon bond forming reaction is particularly useful in the synthesis of macrocycles. Kits, reagents, catalysts, solvents, oxidants, salts, acids, instructions, and other materials useful in the practice of the ivnentive reaction are also provided.

Abstract translation: 已经使用DNA模板化学发现了新的钯介导的碳 - 碳键形成反应。 本发明的反应涉及钯介导的末端炔与烯烃的偶联以形成烯酮。 如果存在氧化剂，催化量的钯可用于反应。 这些反应也与各种有机溶剂以及水溶液相容。 已经证明了分子间和分子内的反应。 这种新的碳 - 碳键形成反应在大环化合物的合成中特别有用。 还提供了可用于实践反应的试剂盒，试剂，催化剂，溶剂，氧化剂，盐，酸，说明书和其它物质。

公开(公告)号：WO2006113331A1

公开(公告)日：2006-10-26

申请号：PCT/US2006/013829

申请日：2006-04-13

Applicant: WYETH ,  THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  YOUNG, Deborah, A. ,  WYNN, Thomas, A. ,  COLLINS, Mary ,  GRUSBY, Michael

Inventor： YOUNG, Deborah, A. ,  WYNN, Thomas, A. ,  COLLINS, Mary ,  GRUSBY, Michael

IPC: C07K14/715 ,  A61P17/02 ,  A61K38/17 ,  C07K16/28 ,  C07K16/24 ,  A61K39/395

CPC classification number: G01N33/6869 ,  A61K33/24 ,  A61K38/13 ,  A61K38/1793 ,  A61K38/20 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/7155 ,  C07K16/244 ,  C07K16/2866 ,  C07K2319/30 ,  G01N2800/00 ,  Y02A50/423 ,  A61K2300/00

Abstract: The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21 R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21 R gene products), and/or the level of interaction of IL-21 with IL-21R).

Abstract translation: 本发明提供了通过测量IL-21和/或IL-21受体（IL-21R）水平的变化来筛选用于治疗，改善或预防纤维化和/或纤维化相关病症的组合物的方法， （例如，IL-21和/或IL-21R蛋白和/或mRNA的表达水平，IL-21和/或IL-21R的活性水平，IL-21与IL- 21R）。 本发明还提供了用于治疗纤维化和/或纤维化相关病症的IL-21或IL-21R拮抗剂。 本文还提供了通过测量IL-21和/或IL-21R的水平来诊断，预测和监测纤维化和/或纤维化相关病症的进展（例如，治疗过程）的方法（即，水平 的IL-21和/或IL-21R的活性，IL-21和/或IL-21R的表达水平（例如，IL-21和/或IL-21R基因产物的水平）和/或 IL-21与IL-21R的相互作用水平）。